Survival trends of patients with metaplastic breast carcinoma with different hormone receptor statuses: a SEER-based retrospective cohort study
Zhiming Miao, Futing Ba, Zechao Wen, Kai Chen, Xiang Shen, Feng Gen, Yinlong Yang · 2024
Read Survival trends of patients with metaplastic breast carcinoma with different hormone receptor statuses: a SEER-based retrospective cohort study by Zhiming Miao, Futing Ba, Zechao Wen, Kai Chen, Xiang Shen, Feng Gen, Yinlong Yang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11590209.txt.
Description
Metaplastic breast cancer is rare, odd under the microscope, and harder to survive than common forms. Zhiming Miao and six co-authors track its survival story across two decades in this 2024 study, drawing more than three thousand patients from a national cancer registry. The split that matters is hormone receptor status, which routes treatment.
Survival improved over the last ten years, but only for the receptor-negative group, in both overall and cancer-specific terms. That group also shifted: more patients arrived with clean lymph nodes, and more received chemotherapy in the later decade. Within subgroups, white patients gained in the negative arm while Black patients gained in the positive arm. The authors read the pattern as progress with an address: it reached some patients and not others.
Catalog record
| CREATOR | Zhiming Miao, Futing Ba, Zechao Wen, Kai Chen, Xiang Shen, Feng Gen, Yinlong Yang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |